WO2016161239A1 - Fgfr/pd-1 combination therapy for the treatment of cancer - Google Patents

Fgfr/pd-1 combination therapy for the treatment of cancer Download PDF

Info

Publication number
WO2016161239A1
WO2016161239A1 PCT/US2016/025482 US2016025482W WO2016161239A1 WO 2016161239 A1 WO2016161239 A1 WO 2016161239A1 US 2016025482 W US2016025482 W US 2016025482W WO 2016161239 A1 WO2016161239 A1 WO 2016161239A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgfr
cancer
antibody
biological sample
fgfr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/025482
Other languages
English (en)
French (fr)
Inventor
Matthew V. Lorenzi
Suso Jesus PLATERO
Raluca VERONA
Jayaprakash Karkera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astex Therapeutics Ltd
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56134542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016161239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CN201680032226.7A priority Critical patent/CN107889462A/zh
Priority to MYPI2017001408A priority patent/MY193705A/en
Priority to EA201792191A priority patent/EA201792191A1/ru
Priority to IL254673A priority patent/IL254673B2/en
Priority to EP16730046.6A priority patent/EP3277319A1/en
Priority to UAA201710675A priority patent/UA126786C2/uk
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Priority to KR1020177031541A priority patent/KR102722130B1/ko
Priority to CA2981603A priority patent/CA2981603A1/en
Priority to JP2017551655A priority patent/JP7134628B2/ja
Priority to SG11201708093VA priority patent/SG11201708093VA/en
Priority to MX2017012552A priority patent/MX2017012552A/es
Priority to NZ736075A priority patent/NZ736075B2/en
Priority to AU2016243917A priority patent/AU2016243917A1/en
Priority to CR20170477A priority patent/CR20170477A/es
Priority to TNP/2017/000421A priority patent/TN2017000421A1/en
Priority to BR112017020973-0A priority patent/BR112017020973A2/en
Publication of WO2016161239A1 publication Critical patent/WO2016161239A1/en
Priority to PH12017501818A priority patent/PH12017501818A1/en
Anticipated expiration legal-status Critical
Priority to CONC2017/0011197A priority patent/CO2017011197A2/es
Priority to AU2022201060A priority patent/AU2022201060A1/en
Priority to AU2025204202A priority patent/AU2025204202A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • an antibody that blocks the interaction between PD-1 and PD-Ll and an FGFR inhibitor for the manufacture of a medicament for the treatment of cancer, in particular for the treatment of cancer in a patient wherein one or more FGFR variants are present in a biological sample from the patient.
  • the medicament contains a pharmaceutically effective amount of an antibody that blocks the interaction between PD-1 and PD-Ll and a pharmaceutically effective amount of an FGFR inhibitor, wherein the medicament is used in a patient wherein one or more FGFR variants are present in a biological sample from the patient.
  • FFPE formalin-fixed, paraffin-embedded
  • NSCLC non-small-cell lung carcinoma
  • SCLC small- cell lung cancer
  • FGFR fibroblast growth factor receptor
  • PD-1 programmeed cell death 1
  • PD-Ll programmeed death-ligand 1
  • FGFR3:TACC3 fusion between genes encoding FGFR3 and transforming acidic coiled-coil containing protein 3
  • FGFR3:BAIAP2L1 fusion between genes encoding FGFR3 and brain-specific angiogenesis inhibitor 1 -associated protein 2-like protein 1
  • FGFR2: AFF3 fusion between genes encoding FGFR2 and AF4 FMR2 family, member 3
  • FGFR2:BICC1 fusion between genes encoding FGFR2 and bi caudal C homolog 1
  • FGFR2: CASP7 fusion between genes encoding FGFR2 and caspase 7
  • FGFR2: CASP7 fusion between genes
  • antibody refers to (a) immunoglobulin polypeptides, i.e., polypeptides of the immunoglobulin family that contain an antigen binding site that specifically binds to a specific antigen (e.g., PD-1 or PD-Ll), including all immunoglobulin isotvpes (IgG, IgA, IgE, IgM, IgD, and IgY), classes (e.g.
  • SNP polymorphism
  • a pharmaceutically effective amount of an antibody that blocks the interaction between PD-1 and PD-Ll and a pharmaceutically effective amount of an FGFR inhibitor wherein the antibody that blocks the interaction between PD-1 and PD-L l and the FGFR inhibitor are administered if PD-Ll expression is high and one or more FGFR variants are present in a biological sample from the patient.
  • the methods can be carried out if the PD-Ll expression is low in the biological sample.
  • the methods can be carried out irrespectively of PD-L1 expression in the biological sample from the patient and can be based on the presence of one or more FGFR variants without factoring in PD-L1 expression.
  • the FGFR variants can be one or more FGFR fusion genes and one or more FGFR amplifications. In some embodiments, the FGFR variants can be one or more FGFR mutations and one or more FGFR amplifications. In yet other words,
  • the evaluating step can further comprise measuring an expression level of PD-L1 in the biological sample and the second administering step can compri se administering the FGFR inhibitor if the expression level of PD-L1 is low.
  • methods of treating cancer in a patient comprise:
  • administering to the patient a pharmaceutically effecti ve amount of an antibody that blocks the interaction between PD-1 and PD-Ll; monitoring the efficacy of the antibody; and if the antibody is not efficacious, evaluating a biological sample from the patient for a presence of one or more FGFR variants and measuring an expression level of PD-Ll in the biological sample, and administering to the patient a pharmaceutically effective amount of an FGFR inhibitor if the one or more FGFR variants are present and if the expression level of PD-Ll is low in the sample.
  • Suitable primer pairs for performing an amplification step include, but are not limited to, those disclosed in U.S. Provisional Patent App. No. 62/056, 159, U.S. Patent
  • the presence of one or more FGFR variants can be evaluated at any suitable time point including upon diagnosis, following tumor resection, following first-line therapy, during clinical treatment, or any combination thereof.
  • the biological sample from which PD-Ll expression is evaluated can be the same biological sample from which the presence of one or more FGFR variants are evaluated, or the biological samples from which PD-Ll expression is evaluated can be a different biological sample from which the presence of one or more FGFR variants are evaluated.
  • “Same biological sample” refers to a single sample from which both PD-Ll expression and FGFR variants are evaluated.
  • “Different biological sample” includes the same source of sample (blood, lymph fluid, bone marrow, a solid tumor sample, etc.) taken at different time points or different sources of sample.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
PCT/US2016/025482 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer Ceased WO2016161239A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
NZ736075A NZ736075B2 (en) 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer
SG11201708093VA SG11201708093VA (en) 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer
EA201792191A EA201792191A1 (ru) 2015-04-03 2016-04-01 Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
IL254673A IL254673B2 (en) 2015-04-03 2016-04-01 Fgfr inhibitor in combination with an antibody that blocks the interaction between pd-1 and pd-l1 as a therapy for the treatment of cancer
EP16730046.6A EP3277319A1 (en) 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer
UAA201710675A UA126786C2 (uk) 2015-04-03 2016-04-01 Fgfr/pd-1 комплексна терапія для лікування раку
MYPI2017001408A MY193705A (en) 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer
KR1020177031541A KR102722130B1 (ko) 2015-04-03 2016-04-01 암 치료를 위한 fgfr/pd-1 조합 요법
CA2981603A CA2981603A1 (en) 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer
JP2017551655A JP7134628B2 (ja) 2015-04-03 2016-04-01 癌治療のためのfgfr/pd-1併用療法
MX2017012552A MX2017012552A (es) 2015-04-03 2016-04-01 Terapia de combinacion del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte propragama 1 (pd-1) para el tratamiento del cancer.
CN201680032226.7A CN107889462A (zh) 2015-04-03 2016-04-01 用于治疗癌症的fgfr/pd‑1组合疗法
BR112017020973-0A BR112017020973A2 (en) 2015-04-03 2016-04-01 Method to Treat Cancer in a Patient
AU2016243917A AU2016243917A1 (en) 2015-04-03 2016-04-01 FGFR/PD-1 combination therapy for the treatment of cancer
CR20170477A CR20170477A (es) 2015-04-03 2016-04-01 Terapia de combinacin del receptor del factor de crecimiento de fibroblastos (fgfr)/muerte programada 1 (pd 1) para el tratamiento del cncer
TNP/2017/000421A TN2017000421A1 (en) 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer
PH12017501818A PH12017501818A1 (en) 2015-04-03 2017-10-03 Fgfr/pd-1 combination therapy for the treatment of cancer
CONC2017/0011197A CO2017011197A2 (es) 2015-04-03 2017-10-31 Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
AU2022201060A AU2022201060A1 (en) 2015-04-03 2022-02-17 Fgfr/pd-1 combination therapy for the treatment of cancer
AU2025204202A AU2025204202A1 (en) 2015-04-03 2025-06-05 Fgfr/pd-1 combination therapy for the treatment of cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562142569P 2015-04-03 2015-04-03
US62/142,569 2015-04-03
US15/079,136 2016-03-24
US15/079,136 US10478494B2 (en) 2015-04-03 2016-03-24 FGFR/PD-1 combination therapy for the treatment of cancer

Publications (1)

Publication Number Publication Date
WO2016161239A1 true WO2016161239A1 (en) 2016-10-06

Family

ID=56134542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/025482 Ceased WO2016161239A1 (en) 2015-04-03 2016-04-01 Fgfr/pd-1 combination therapy for the treatment of cancer

Country Status (23)

Country Link
US (3) US10478494B2 (cg-RX-API-DMAC7.html)
EP (1) EP3277319A1 (cg-RX-API-DMAC7.html)
JP (1) JP7134628B2 (cg-RX-API-DMAC7.html)
KR (1) KR102722130B1 (cg-RX-API-DMAC7.html)
CN (1) CN107889462A (cg-RX-API-DMAC7.html)
AU (3) AU2016243917A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017020973A2 (cg-RX-API-DMAC7.html)
CA (1) CA2981603A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017002481A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017011197A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170477A (cg-RX-API-DMAC7.html)
EA (1) EA201792191A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17072756A (cg-RX-API-DMAC7.html)
IL (1) IL254673B2 (cg-RX-API-DMAC7.html)
MA (1) MA41858A (cg-RX-API-DMAC7.html)
MX (1) MX2017012552A (cg-RX-API-DMAC7.html)
MY (2) MY205639A (cg-RX-API-DMAC7.html)
PE (1) PE20180131A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501818A1 (cg-RX-API-DMAC7.html)
SG (2) SG11201708093VA (cg-RX-API-DMAC7.html)
TN (1) TN2017000421A1 (cg-RX-API-DMAC7.html)
UA (1) UA126786C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016161239A1 (cg-RX-API-DMAC7.html)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10039759B2 (en) 2011-10-28 2018-08-07 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US10045982B2 (en) 2011-10-28 2018-08-14 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US10052320B2 (en) 2011-10-28 2018-08-21 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US10272087B2 (en) 2012-05-30 2019-04-30 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US10421747B2 (en) 2014-03-26 2019-09-24 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US10519137B2 (en) 2010-04-30 2019-12-31 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
JP2020505425A (ja) * 2017-02-06 2020-02-20 ヤンセン ファーマシューティカ エヌ.ベー. 癌治療
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
WO2021160763A1 (en) * 2020-02-12 2021-08-19 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
US11149090B2 (en) 2014-08-12 2021-10-19 Alligator Bioscience Ab Combination therapies with anti CD40 antibodies
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
EP3932427A4 (en) * 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY USING A 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND AND PEMBROLIZUMAB
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11789010B2 (en) 2017-04-28 2023-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
WO2024120084A1 (zh) * 2022-12-07 2024-06-13 宜明昂科生物医药技术(上海)股份有限公司 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法
RU2822064C2 (ru) * 2019-02-28 2024-07-01 Тайхо Фармасьютикал Ко., Лтд. Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и пембролизумаба
WO2025047922A1 (ja) 2023-08-31 2025-03-06 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法
US12252535B2 (en) 2014-03-14 2025-03-18 Novartis Ag Antibody molecules to LAG-3 and uses thereof
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
US12600777B2 (en) 2015-07-29 2026-04-14 Novartis Ag Combination therapies comprising antibody molecules to LAG-3
US12630633B2 (en) 2015-12-17 2026-05-19 Novartis Ag Antibody molecules to PD-1 and uses thereof
US12662523B2 (en) 2019-05-03 2026-06-23 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing CD80 extracellular domain-Fc fusion proteins
US12691112B2 (en) 2019-03-29 2026-07-28 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
DK3023100T3 (da) 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3303632B2 (en) * 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Therapeutic and diagnostic methods for cancer
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling
CN108440673B (zh) * 2018-04-08 2021-08-17 海南医学院 Fc融合蛋白PD1/FGFR1及其应用
JP2022524629A (ja) * 2019-03-15 2022-05-09 重▲慶▼医葯工▲業▼研究院有限責任公司 抗腫瘍薬の調製におけるキノリン誘導体と免疫調節剤の組み合わせの使用
US20220348662A1 (en) * 2019-09-26 2022-11-03 Janssen Pharmaceutica Nv Use of fgfr inhibitors in fgfr-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings
CN111420060B (zh) * 2020-03-30 2022-04-08 南方医科大学南方医院 一种抗肿瘤的联合用药组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135376A1 (en) * 2010-04-30 2011-11-03 Astex Therapeutics Limited Pyrazolyl quinazoline kinase inhibitors
WO2014165422A1 (en) * 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2016048833A2 (en) 2014-09-26 2016-03-31 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Family Cites Families (222)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5843941A (en) 1993-05-14 1998-12-01 Genentech, Inc. Ras farnesyl transferase inhibitors
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
JP4130700B2 (ja) 1996-02-26 2008-08-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗腫瘍剤含有組成物
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
ES2235331T3 (es) 1997-05-28 2005-07-01 Aventis Pharmaceuticals Inc Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck.
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
EP1208231B2 (en) 1999-05-05 2009-12-30 Institut Curie Means for detecting and treating pathologies linked to fgfr3
JP2003509425A (ja) 1999-09-15 2003-03-11 ワーナー−ランバート・カンパニー キナーゼ阻害剤としてのプテリジノン
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030235628A1 (en) 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
JP4286146B2 (ja) 2001-12-18 2009-06-24 メルク エンド カムパニー インコーポレーテッド メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
US6962995B2 (en) 2002-07-10 2005-11-08 E. I. Du Pont De Nemours And Company Charge transport compositions and electronic devices made with such compositions
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
MXPA05003477A (es) 2002-10-03 2005-07-22 Targegen Inc Agentes vasculo-estaticos y metodos de uso de los mismos.
AU2003301654A1 (en) 2002-10-22 2004-05-13 Dainippon Pharmaceutical Co., Ltd. Stabilized composition
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
EP1590341B1 (en) 2003-01-17 2009-06-17 Warner-Lambert Company LLC 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
WO2004104003A1 (de) 2003-05-23 2004-12-02 Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
EP1646383A4 (en) 2003-07-21 2009-03-25 Bethesda Pharmaceuticals Inc DESIGN AND SYNTHESIS OF OPTIMIZED LIGANDS FOR PPAR
BRPI0413234A (pt) 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
PT1673092E (pt) 2003-10-17 2007-11-23 4 Aza Ip Nv ''derivados de pteridina substituídos com heterociclos e sua utilização em terapia''
EP1694308A1 (en) 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
JP4823914B2 (ja) 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Fgfr3の阻害および多発性骨髄腫の治療
NZ546991A (en) 2003-11-20 2010-01-29 Janssen Pharmaceutica Nv 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
BRPI0416853A (pt) 2003-11-24 2007-02-13 Hoffmann La Roche pirazolila e imidazolila pirimidinas
EP2228369A1 (en) 2003-12-23 2010-09-15 Astex Therapeutics Ltd. Pyrazole derivatives as protein kinase modulators
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US20090118261A1 (en) 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
KR20080075235A (ko) 2004-10-14 2008-08-14 에프. 호프만-라 로슈 아게 Cdk1 항증식성 활성을 갖는 1,5-나프티리딘 아졸리디논
CA2583096A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
EP1827393A4 (en) 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
NZ555334A (en) 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
EP1833469A2 (en) 2005-01-03 2007-09-19 Lupin Ltd. Pharmaceutical composition of acid labile substances
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
EP1853261B1 (de) 2005-03-03 2017-01-11 Universität des Saarlandes Selektive hemmstoffe humaner corticoidsynthasen
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
AU2006247833A1 (en) 2005-05-12 2006-11-23 Merck & Co., Inc. Tyrosine kinase inhibitors
SI1901729T1 (sl) 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
BRPI0611521A2 (pt) 2005-05-18 2010-09-14 Wyeth Corp inibidores de 4,6-diamino-[1,7]naftiridina-3-carbonitrila de quìnase tpl2 e métodos de fabricação e uso dos mesmos
CN101237890A (zh) 2005-06-10 2008-08-06 中外制药株式会社 含有葡甲胺的蛋白质制剂的稳定剂及其利用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
ZA200801822B (en) 2005-08-26 2009-09-30 Serono Lab Pyrazine derivatives and use as p13k inhibitors
HRP20140975T1 (hr) 2005-10-07 2014-11-21 Exelixis, Inc. Derivati n-(3-amino-hinoksalin-2-il)-sulfonamida i njihova uporaba kao inhibitora fosfatidilinozitol 3-kinaze
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
AU2006313701B2 (en) 2005-11-11 2012-05-31 Aeterna Zentaris Gmbh Novel pyridopyrazines and their use as modulators of kinases
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
CN1966500B (zh) 2005-11-17 2011-03-30 中国科学院上海药物研究所 一类喹喔啉类衍生物、制法及用途
US20090247576A1 (en) 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
WO2007125405A2 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
WO2007135027A1 (de) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
AU2007271187A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
JP5244118B2 (ja) 2006-11-10 2013-07-24 ブリストル−マイヤーズ スクイブ カンパニー 新規キナーゼ阻害剤
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc 1,5−ナフチリジン化合物及び有機発光素子
EP2104501B1 (en) 2006-12-13 2014-03-12 Merck Sharp & Dohme Corp. Methods of cancer treatment with igf1r inhibitors
RU2009122670A (ru) 2006-12-21 2011-01-27 Плекссикон, Инк. (Us) Соединения и способы для модуляции киназ и показания к их применению
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
EP2154965A4 (en) 2007-05-29 2011-08-17 Glaxosmithkline Llc NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
ES2442003T3 (es) 2007-06-20 2014-02-07 Mitsubishi Tanabe Pharma Corporation Nuevo derivado de sulfonamida de ácido malónico y uso farmacéutico del mismo
EP2170894A1 (en) 2007-06-21 2010-04-07 Janssen Pharmaceutica N.V. Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
JP2010532758A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 組み合わせ抗癌療法
EP2188292B1 (en) 2007-08-08 2013-05-29 GlaxoSmithKline Intellectual Property Development Limited 2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害薬としてのキノキサリン誘導体
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
WO2013173485A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancers
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
WO2009080541A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110129456A1 (en) 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
BR122020021551B1 (pt) 2008-11-15 2021-09-21 Melinta Subsidiary Corp Composição farmacêutica antimicrobiana e seu uso
EP2356116A1 (en) 2008-11-20 2011-08-17 OSI Pharmaceuticals, Inc. Substituted pyrroloý2,3-b¨-pyridines and-pyrazines
US8716280B2 (en) 2009-01-21 2014-05-06 Basilea Pharmaceutica Ag Bicyclic antibiotics
WO2010088177A1 (en) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibitors of akt activity
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
CN102625804B (zh) 2009-06-12 2015-04-08 Abivax公司 用于治疗aids的化合物
DK2473504T3 (en) 2009-09-03 2015-03-16 Bioenergenix Heterocyclic Compounds for Inhibition of Passover
WO2011026579A1 (en) 2009-09-04 2011-03-10 Bayer Schering Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
CA2772275A1 (en) 2009-09-18 2011-03-24 Sanofi (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
JP5894980B2 (ja) 2010-05-24 2016-03-30 インテリカイン, エルエルシー 複素環式化合物およびその使用
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1,2,4]三唑并[4,3-b][1,2,4]三嗪类化合物、其制备方法和用途
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ,エルエルシー 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
AU2012308238B2 (en) 2011-09-14 2017-05-25 Neupharma, Inc. Certain chemical entities, compositions, and methods
US9249110B2 (en) 2011-09-21 2016-02-02 Neupharma, Inc. Substituted quinoxalines as B-raf kinase inhibitors
EP2761300A4 (en) 2011-09-27 2015-12-02 Univ Michigan Recurrent genital fusion in breast cancer
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
KR20220017512A (ko) 2012-03-08 2022-02-11 아스테라스 세이야쿠 가부시키가이샤 신규 fgfr3 융합체
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
CA2866321A1 (en) 2012-04-03 2013-10-10 Novartis Ag Tyrosine kinase inhibitor combinations and their use
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
WO2014007369A1 (ja) 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Fgfr2融合遺伝子
WO2014011629A1 (en) 2012-07-09 2014-01-16 Coherus Biosciences, Inc. Stable aqueous formulations of etanercept
CA2880013C (en) 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20150203589A1 (en) * 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
BR112015001724A2 (pt) 2012-07-27 2018-04-03 Genentech Inc métodos de tratamento de condições relacionadas a fgfr3
WO2014028461A2 (en) 2012-08-13 2014-02-20 The Rockefeller University Treatment and diagnosis of melanoma
EA031631B1 (ru) 2012-09-27 2019-01-31 Чугаи Сеияку Кабушики Каиша Способ лечения или предупреждения злокачественного новообразования, способ отбора пациента, способ тестирования предрасположенности к злокачественному новообразованию у субъекта, гибридный полипептид и его применения
EP4223770A3 (en) 2012-11-05 2023-10-18 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
EA201590788A1 (ru) 2012-11-07 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Аминные соли лахинимода
CA2898326C (en) 2013-01-18 2022-05-17 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
WO2014165710A2 (en) 2013-04-05 2014-10-09 Life Technologies Corporation Gene fusions
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3004380A2 (en) 2013-05-27 2016-04-13 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
EP3007681A1 (en) 2013-06-14 2016-04-20 Synthon B.V. Stable and water soluble pharmaceutical compositions comprising pemetrexed
WO2014201111A1 (en) 2013-06-14 2014-12-18 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
EP3019628A4 (en) 2013-07-12 2017-05-10 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
EP3027623A4 (en) 2013-08-02 2017-03-01 Ignyta, Inc. METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
WO2015100257A1 (en) 2013-12-23 2015-07-02 The General Hospital Corporation Methods and assays for determining reduced brca1 pathway function in a cancer cell
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
BR112016022056B1 (pt) 2014-03-26 2023-04-11 Astex Therapeutics Limited Combinação, composição farmacêutica, uso de uma combinação ou uma composição farmacêutica, e, produto farmacêutico
CA2949327A1 (en) 2014-05-29 2015-12-03 Medimmune Limited Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
EP3164121A4 (en) 2014-07-01 2018-06-13 Vicus Therapeutics, LLC Combination drug therapies for cancer and methods of making and using them
CN112546230A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
EA201790543A1 (ru) 2014-09-08 2017-07-31 Селджин Корпорейшн Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
US20170275705A1 (en) 2014-09-15 2017-09-28 The Johns Hopkins University Biomarkers useful for determining response to pd-1 blockade therapy
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
JP2018502123A (ja) 2015-01-20 2018-01-25 イミューンエクサイト, インコーポレイテッド 癌免疫療法のための組成物及び方法
TWI719960B (zh) 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
SG11201706727XA (en) * 2015-02-19 2017-09-28 Bioclin Therapeutics Inc Methods, compositions, and kits for treatment of cancer
AR103726A1 (es) 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX386547B (es) 2015-03-04 2025-03-19 Merck Sharp & Dohme Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
AU2016235434B2 (en) 2015-03-20 2022-02-03 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
US20180044418A1 (en) 2015-03-20 2018-02-15 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and vorinostat for treating cancer
US10426847B2 (en) 2015-03-26 2019-10-01 Oncosec Medical Incorporated Method for the treatment of malignancies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
US20160347836A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
WO2016196389A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
PT3313443T (pt) 2015-06-25 2023-08-30 Immunomedics Inc Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
EA201890161A1 (ru) 2015-06-29 2018-06-29 Верастэм, Инк. Терапевтические композиции, комбинации и способы применения
CN105030777B (zh) 2015-07-14 2017-07-21 中国人民解放军第三军医大学第三附属医院 增强alk‑tki疗效、延缓其耐药的复合物及其制剂
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
US20170021019A1 (en) 2015-07-22 2017-01-26 Matthew Zibelman COMBINATION OF IMMUNOMODULATORY AGENT WITH PD-1 or PD-L1 CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
CN105147687A (zh) 2015-09-28 2015-12-16 青岛华之草医药科技有限公司 一种治疗白血病的药物达沙替尼组合物胶囊
SG10201913538VA (en) 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
ES2913208T3 (es) 2015-12-01 2022-06-01 Glaxosmithkline Ip Dev Ltd Tratamientos de combinación y usos y métodos de los mismos
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135376A1 (en) * 2010-04-30 2011-11-03 Astex Therapeutics Limited Pyrazolyl quinazoline kinase inhibitors
US20130072457A1 (en) 2010-04-30 2013-03-21 Astex Therapeutics Limited Pyrazolyl quinazoline kinase inhibitors
WO2014165422A1 (en) * 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2015112900A1 (en) * 2014-01-24 2015-07-30 Dana-Farber Cancer Institue, Inc. Antibody molecules to pd-1 and uses thereof
WO2016048833A2 (en) 2014-09-26 2016-03-31 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
US20160090633A1 (en) 2014-09-26 2016-03-31 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ALEJO RODRIGUEZ-VIDA ET AL: "Complexity of FGFR signalling in metastatic urothelial cancer", JOURNAL OF HEMATOLOGY & ONCOLOGY, BIOMED CENTRAL LTD, LONDON UK, vol. 8, no. 1, 24 October 2015 (2015-10-24), pages 119, XP021230975, ISSN: 1756-8722, DOI: 10.1186/S13045-015-0221-6 *
BERGE: "Pharmaceuticall Acceptable Salts", J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
GURU SONPAVDE ET AL: "Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 23, no. 3, 3 January 2014 (2014-01-03), UK, pages 305 - 315, XP055250650, ISSN: 1354-3784, DOI: 10.1517/13543784.2014.871259 *
HAN KIAT HO ET AL: "Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations", DRUG DISCOVERY TODAY., vol. 19, no. 1, 1 January 2014 (2014-01-01), US, pages 51 - 62, XP055291843, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2013.07.021 *
HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
JAMES D. MARKS: "Antibody Engineering", 1995, OXFORD UNIVERSITY PRESS, article "Chapter 2,"
R. MOREIRA DA SILVA: "Nivolumab: Anti-PD-1 monoclonal antibody cancer immunotherapy", DRUGS OF THE FUTURE, vol. 39, no. 1, 1 January 2014 (2014-01-01), ES, pages 15 - 24, XP055199597, ISSN: 0377-8282, DOI: 10.1358/dof.2014.039.01.2103754 *
See also references of EP3277319A1

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519137B2 (en) 2010-04-30 2019-12-31 Astex Therapeutics Ltd Pyrazolyl quinoxaline kinase inhibitors
US10039759B2 (en) 2011-10-28 2018-08-07 Astex Therapeutics Ltd Quinolines as FGFR kinase modulators
US10052320B2 (en) 2011-10-28 2018-08-21 Astex Therapeutics Ltd Substituted quinoxalines as FGFR kinase inhibitors
US10045982B2 (en) 2011-10-28 2018-08-14 Astex Therapeutics Ltd Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors
US10272087B2 (en) 2012-05-30 2019-04-30 Astex Therapeutics Ltd Pteridines as FGFR inhibitors
US11708412B2 (en) 2013-09-26 2023-07-25 Novartis Ag Methods for treating hematologic cancers
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US10752687B2 (en) 2014-01-24 2020-08-25 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11827704B2 (en) 2014-01-24 2023-11-28 Novartis Ag Antibody molecules to PD-1 and uses thereof
US10472419B2 (en) 2014-01-31 2019-11-12 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US11155620B2 (en) 2014-01-31 2021-10-26 Novartis Ag Method of detecting TIM-3 using antibody molecules to TIM-3
US10981990B2 (en) 2014-01-31 2021-04-20 Novartis Ag Antibody molecules to TIM-3 and uses thereof
US12252535B2 (en) 2014-03-14 2025-03-18 Novartis Ag Antibody molecules to LAG-3 and uses thereof
US10421747B2 (en) 2014-03-26 2019-09-24 Astex Therapeutics Ltd Quinoxaline derivatives useful as FGFR kinase modulators
US10736900B2 (en) 2014-03-26 2020-08-11 Astex Therapeutics Ltd Combinations of an FGFR inhibitor and an IGF1R inhibitor
US10716787B2 (en) 2014-03-26 2020-07-21 Astex Therapeutics Ltd Combinations
US11918576B2 (en) 2014-03-26 2024-03-05 Astex Therapeutics Ltd Combination of an FGFR inhibitor and a CMET inhibitor
US10085982B2 (en) 2014-03-26 2018-10-02 Astex Therapeutics Ltd Combinations
US12570753B2 (en) 2014-08-12 2026-03-10 Alligator Bioscience Ab Combination therapies with anti CD40 antibodies
US11149090B2 (en) 2014-08-12 2021-10-19 Alligator Bioscience Ab Combination therapies with anti CD40 antibodies
US11344620B2 (en) 2014-09-13 2022-05-31 Novartis Ag Combination therapies
US10898482B2 (en) 2015-02-10 2021-01-26 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US11684620B2 (en) 2015-02-10 2023-06-27 Astex Therapeutics Ltd Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US12678498B2 (en) 2015-04-03 2026-07-14 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
US12600777B2 (en) 2015-07-29 2026-04-14 Novartis Ag Combination therapies comprising antibody molecules to LAG-3
US11542247B2 (en) 2015-09-23 2023-01-03 Janssen Pharmaceutica Nv Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer
US11155555B2 (en) 2015-09-23 2021-10-26 Janssen Pharmaceutica Nv Compounds
US11098103B2 (en) 2015-11-02 2021-08-24 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US12630633B2 (en) 2015-12-17 2026-05-19 Novartis Ag Antibody molecules to PD-1 and uses thereof
US11975002B2 (en) 2016-03-04 2024-05-07 Taiho Pharmaceutical Co., Ltd. Preparation and composition for treatment of malignant tumors
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7884578B2 (ja) 2017-02-06 2026-07-03 ヤンセン ファーマシューティカ エヌ.ベー. 癌治療
JP2023022190A (ja) * 2017-02-06 2023-02-14 ヤンセン ファーマシューティカ エヌ.ベー. 癌治療
JP2020505425A (ja) * 2017-02-06 2020-02-20 ヤンセン ファーマシューティカ エヌ.ベー. 癌治療
JP7668777B2 (ja) 2017-02-06 2025-04-25 ヤンセン ファーマシューティカ エヌ.ベー. 癌治療
JP2025024064A (ja) * 2017-02-06 2025-02-19 ヤンセン ファーマシューティカ エヌ.ベー. 癌治療
US11789010B2 (en) 2017-04-28 2023-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
US11833151B2 (en) 2018-03-19 2023-12-05 Taiho Pharmaceutical Co., Ltd. Pharmaceutical composition including sodium alkyl sulfate
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
EP3932425A4 (en) * 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY WITH 3,5-DISUBSTITUTED BENZENE ALKINYL COMPOUND AND IMMUNE CHECKPOINT INHIBITOR
KR20260085357A (ko) 2019-02-28 2026-06-09 다이호야쿠힌고교 가부시키가이샤 3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
RU2822064C2 (ru) * 2019-02-28 2024-07-01 Тайхо Фармасьютикал Ко., Лтд. Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и пембролизумаба
RU2843836C2 (ru) * 2019-02-28 2025-07-18 Тайхо Фармасьютикал Ко., Лтд. Противораковая терапия с применением соединений 3,5-дизамещенного бензолалкинила и ингибитора иммунной контрольной точки
EP3932427A4 (en) * 2019-02-28 2022-12-07 Taiho Pharmaceutical Co., Ltd. CANCER THERAPY USING A 3,5-DISUBSTITUTED BENZOLALKYNYL COMPOUND AND PEMBROLIZUMAB
KR20260085356A (ko) 2019-02-28 2026-06-09 다이호야쿠힌고교 가부시키가이샤 3,5-2치환 벤젠알키닐 화합물과 면역 체크포인트 저해약을 사용한 암 치료법
US12691112B2 (en) 2019-03-29 2026-07-28 Janssen Pharmaceutica Nv FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US12662523B2 (en) 2019-05-03 2026-06-23 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing CD80 extracellular domain-Fc fusion proteins
WO2021160763A1 (en) * 2020-02-12 2021-08-19 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
TWI900527B (zh) * 2020-02-12 2025-10-11 比利時商健生藥品公司 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑
WO2024120084A1 (zh) * 2022-12-07 2024-06-13 宜明昂科生物医药技术(上海)股份有限公司 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法
WO2025047922A1 (ja) 2023-08-31 2025-03-06 大鵬薬品工業株式会社 3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法

Also Published As

Publication number Publication date
MX2017012552A (es) 2018-08-01
EP3277319A1 (en) 2018-02-07
CL2017002481A1 (es) 2018-03-16
AU2016243917A1 (en) 2017-10-26
US10478494B2 (en) 2019-11-19
MY193705A (en) 2022-10-26
CA2981603A1 (en) 2016-10-06
CR20170477A (es) 2018-04-20
US12678498B2 (en) 2026-07-14
AU2025204202A1 (en) 2025-06-26
AU2022201060A1 (en) 2022-03-10
CN107889462A (zh) 2018-04-06
IL254673B2 (en) 2023-12-01
ECSP17072756A (es) 2018-04-30
US20200108141A1 (en) 2020-04-09
IL254673A0 (en) 2017-11-30
IL254673B1 (en) 2023-08-01
EA201792191A1 (ru) 2018-02-28
US20160287699A1 (en) 2016-10-06
KR102722130B1 (ko) 2024-10-28
KR20170132859A (ko) 2017-12-04
JP7134628B2 (ja) 2022-09-12
BR112017020973A2 (en) 2018-07-10
PH12017501818A1 (en) 2018-04-23
SG11201708093VA (en) 2017-10-30
MY205639A (en) 2024-11-01
NZ736075A (en) 2025-02-28
UA126786C2 (uk) 2023-02-08
SG10202100562RA (en) 2021-03-30
MA41858A (fr) 2018-02-06
JP2018511611A (ja) 2018-04-26
TN2017000421A1 (en) 2019-01-16
US20230030983A1 (en) 2023-02-02
CO2017011197A2 (es) 2018-03-28
PE20180131A1 (es) 2018-01-18

Similar Documents

Publication Publication Date Title
US20230030983A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
Wang et al. Recent advances on the roles of epidermal growth factor receptor in psoriasis
Mancini et al. An oligoclonal antibody durably overcomes resistance of lung cancer to third‐generation EGFR inhibitors
Vishwamitra et al. Type I insulin-like growth factor receptor signaling in hematological malignancies
US20230227918A1 (en) Predictive and diagnostic methods for prostate cancer
Sengupta et al. CXCR4 activation defines a new subgroup of sonic Hedgehog–driven medulloblastoma
KR101960431B1 (ko) Her2 양성 암 및 항-her2 치료에 대한 바이오마커 및 이의 용도
US20240093304A1 (en) Alk fusion genes and uses thereof
JP2024527109A (ja) Kras変異体がんの処置のための方法および組成物
Chen et al. Frequent B7-H3 overexpression in craniopharyngioma
Servidei et al. Novel SEC61G–EGFR fusion gene in pediatric ependymomas discovered by clonal expansion of stem cells in absence of exogenous mitogens
Hu et al. Mechanism of LINC01018/miR-182-5p/Rab27B in the immune escape through PD-L1-mediated CD8+ T cell suppression in glioma
US20220025036A1 (en) Use of il-1beta binding antibodies
WO2022241293A9 (en) Cd274 mutations for cancer treatment
Schauer et al. Autocrine signaling in hormonally active cancer induces antigen expression for immunotherapy
TWI703984B (zh) 用於癌症治療之fgfr/pd-1組合療法
JP2021523098A (ja) T細胞による認識を強化するよう抗原性を調節する方法
EA047812B1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
US20250383345A1 (en) Methods and agents for determining patient status
Amato et al. 559 ERBB4 is a Therapeutic Target in Melanoma Resistant to Braf Inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16730046

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 254673

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/012552

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2017551655

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017-000119 I

Country of ref document: NI

Ref document number: 11201708093V

Country of ref document: SG

ENP Entry into the national phase

Ref document number: 2981603

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 001827-2017

Country of ref document: PE

Ref document number: 12017501818

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017020973

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: CR2017-000477

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2016243917

Country of ref document: AU

Date of ref document: 20160401

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20177031541

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2017/0011197

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 201792191

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: NC2017/0011197

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 112017020973

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170929

WWR Wipo information: refused in national office

Ref document number: NC2017/0011197

Country of ref document: CO

WWG Wipo information: grant in national office

Ref document number: 736075

Country of ref document: NZ